8th Jul 2020 15:51
MaxCyte Inc - cell and gene therapies - Signs clinical and commercial licensing agreement with Apeiron Biologics AG. Apeiron to obtain non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPert platform for advancing APN401, a cell-therapy in development for solid tumours. MaxCyte will receive undisclosed development and approval milestones, with sales-based payments and licensing fees.
Current stock price: 208.80 pence
Year-to-date change: up 69%
By Dayo Laniyan; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
MaxCyte